Onconetix, Inc. Files 8-K on Shareholder Votes & Financials
Ticker: ONCO · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1782107
Sentiment: neutral
Topics: corporate-governance, financials, filing-update
TL;DR
Onconetix (ONCO) filed an 8-K covering shareholder votes and financials as of Sept 5. Stay tuned.
AI Summary
Onconetix, Inc. filed an 8-K on September 11, 2024, reporting on matters submitted to a vote of security holders and financial statements as of September 5, 2024. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.
Why It Matters
This filing provides updates on corporate governance and financial status, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on standard corporate events and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
- September 5, 2024 (date) — Date of earliest event reported
- September 11, 2024 (date) — Date of report
- 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the date of the financial statements being reported?
The financial statements are as of September 5, 2024.
When was Onconetix, Inc. previously known?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.
In which state is Onconetix, Inc. incorporated?
Onconetix, Inc. is incorporated in Delaware.
What is the address of Onconetix, Inc.'s principal executive offices?
The principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
Filing Stats: 1,169 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2024-09-10 18:04:32
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $5 million — Stock to be issued by the Company in a $5 million private placement financing of units, w
Filing Documents
- ea0214181-8k_onconetix.htm (8-K) — 49KB
- 0001213900-24-077457.txt ( ) — 221KB
- onco-20240905.xsd (EX-101.SCH) — 3KB
- onco-20240905_lab.xml (EX-101.LAB) — 33KB
- onco-20240905_pre.xml (EX-101.PRE) — 22KB
- ea0214181-8k_onconetix_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 5, 2024, Onconetix, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). The matters voted on at the Annual Meeting were: (1) the election of Timothy Ramdeen and Ajit Singh to serve as Class III directors on the Board for a three-year term that expires at the 2027 Annual Meeting of Stockholders, or until their successors are elected and qualified (the "Director Election Proposal"); (2) the approval of amendments to the Company's 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 54,850,000 shares from 3,150,000 to 58,000,000 shares (the "2022 Plan Proposal"); (3) the adoption and approval of the Amendment to effect a reverse stock split of all of the outstanding shares of Common Stock, at a ratio in the range of one-for-thirty (1:30) to one-for-sixty (1:60), with such ratio to be determined by the Board (the "Reverse Stock Split Proposal"); (4) the approval of, in accordance with Nasdaq Listing Rule 5635, the issuance of up to 5,709,935 shares of Common Stock, subject to adjustment, upon conversion of the Company's Series A Preferred Stock, par value $0.00001 per share (the "Series A Conversion Proposal"); (5) the approval of, in accordance with Nasdaq Listing Rule 5635, the issuance of: (i) 269,672,900 shares of Common Stock to be issued upon conversion of the Company's Series B Preferred Stock, par value $0.00001 per share, (ii) such number of shares of Common Stock to be issued by the Company in a $5 million private placement financing of units, which shall initially include 20,000,000 shares of Common Stock and up to 6,000,000 shares of Common Stock underlying warrants included in the units, subject to adjustment, plus such additional number of shares of Common Stock to be issuable upon the satisfaction of certain price protection conditions, as described further herei
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. September 10, 2024 By: /s/ Karina M. Fedasz Name: Karina M. Fedasz Title: Interim Chief Financial Officer 4